Study of serum cholinesterase as a biomarker in a sample of patients with viral hepatitis B or hepatitis C in Baghdad
Keywords:
HBV, HCV, serum cholinesteraseAbstract
The most prevalent illnesses that affect the liver are viral infections; when the liver cell is destroyed by viruses, it loses its function and most of the body's processes are compromised. The liver is the primary source of serum cholinesterase. Therefore, serum cholinesterase can be used as a predictive biomarker for the liver's synthetic capability. This study aims to evaluate serum cholinesterase as a biomarker in patients with hepatitis B virus (HBV) or hepatitis C virus (HCV). The study was conducted at the Gastroenterology and Hepatology Teaching Hospital and Poisoning Consultation Center in Baghdad during the interval from November 2021 to March 2022. The liver function tests and serum cholinesterase were measured in one hundred fifty samples. Fifty patients with HBV and fifty patients with HCV were compared with fifty healthy individuals as a control group. The mean serum cholinesterase in the HBV and HCV patient groups (8528.76±2000.45 U/L and 7494.12± 2586.30 U/L, respectively) was lower than in the control group (9380.12±1848.96 U/L), and the difference was statistically significant (P < 0.05). The mean serum cholinesterase in the HCV patient group (7494.12±2586.30 U/L) was significantly lower (P < 0.05) than in the HBV patient group (8528.76 ±2000.45 U/L).
Downloads
References
Kozeniecki M, Ludke R, Kerner J, Patterson B. Micronutrients in liver disease: roles, risk factors for deficiency, and recommendations for supplementation. Nutr Clin Pract. 2020;35(1):50–62.
Terrault NA, Bzowej NH, Chang K, Hwang JP, Jonas MM, Murad MH. A ASLD guidelines for treatment of chronic hepatitis B. Hepatology. 2016;63(1):261–83.
Van der Meer AJ, Feld JJ, Hofer H, Almasio PL, Calvaruso V, Fernández-Rodríguez CM, et al. Risk of cirrhosis-related complications in patients with advanced fibrosis following hepatitis C virus eradication. J Hepatol. 2017;66(3):485–93.
Chowdhry V, Kaushik G, Demonstrator, Professor S, Hod. “ Estimation of 5’ Nucleotidase and Serum Cholinesterase as Diagnostic Marker to Distinguish Between Various Liver Diseases and Non Liver Diseases ”. SSRG Int J Med Sci. 2017; 4(8), 3–6
Mohamed NAA, Amanullah M, Amanvermez R, Ibrahim MA, Abbas M. Serum cholinesterase as liver function test in cirrhotic patients at Soba Teaching hospital, Khartoum, Sudan. Int Res J Med Med Sci. 2017;5(3):44–9.
Aboughazala LM. Study on Serum Cholinesterase as Marker of Chronic Liver Disease. Al-Azhar Univ J Virus Res Stud. 2020;2(1):1–15.
Jasiecki J, Jońca J, Żuk M, Szczoczarz A, Janaszak-Jasiecka A, Lewandowski K, Waleron K, & Wasąg B. Activity and polymorphisms of butyrylcholinesterase in a Polish population. Chem Biol Interact. 2016;259:70–7.
Pohanka M. Voltammetric assay of butyrylcholinesterase in plasma samples and its comparison to the standard spectrophotometric test. Talanta. 2014;119:412–16.
Chen G, Feng H, Jiang X, Xu J, Pan S, Qian Z. Redox-controlled fluorescent nanoswitch based on reversible disulfide and its application in butyrylcholinesterase activity assay. Anal Chem. 2018;90(3):1643–51.
Jalil AT, Dilfy SH, Karevskiy A, Najah N. Viral Hepatitis in Dhi-Qar Province: Demographics and Hematological Characteristics of Patients. Int J Pharm Res. 2020;12(1):2081–7.
Kadhem SB, Jumaa ZMEMG, Rhaymah MS. Prevalence of Viral Hepatitis Infections in Misan Province, Iraq, 2013 through 2017. J Pharm Sci Res. 2019;11(4):1263–8.
Kwo PY, Cohen SM, Lim JK. ACG Clinical Guideline: Evaluation of Abnormal Liver Chemistries. Am J Gastroenterol. 2017 Jan;112(1):18–35.
Haklar G. Liver function tests in chronic viral hepatitis cases. Marmara Med J. 2016;29(2):6–9.
Kalas MA, Chavez L, Leon M, Taweesedt PT, Surani S. Abnormal liver enzymes: A review for clinicians. World J Hepatol. 2021;13(11):1688.
Al-Madany NA, Sarhat ER. Determination of Some Biochemical Parameters of Patients with Hepatitis B in Kirkuk City. Kirkuk Univ J Sci Stud. 2018;13(2):139–48.
Vyas S, Vyas RK, Sharma H. Role of Serum Cholinesterase and 5-Nucleotidase Enzyme Activity in the Diagnosis of Alcoholic and Non-Alcoholic Liver Disease and Compared With Healthy Subjects of Rajasthan. Saudi J Med Pharm Sci. 2019; 5(12), 1120-1126
Hassan ZSY, Tahoun AMAR, Eldahshan MAK, Abo-Zied AAH. Evaluation of Serum Cholinesterase Level as A diagnostic Marker in Chronic Liver Disease. Al-Azhar Med J. 2021;50(3):2331–6.
Salama SSA, El-Bahnasawy BE-DE-S, Hashish MAE, Ebiary A, Mustafa MM. Serum Cholinesterase Level as a Biomarker in Detecting Liver Injury in Patients with Chronic Hepatitis C. Egypt J Hosp Med. 2019;76(7):4662–8.
Roshankumar Jha DMP, Mahajan SN. Study of assessment of level of serum cholinesterase in patients with liver diseases. Indian J Basic Appl Med Res. 2019; 9(1), 460–5.
Caccamo G, Saffioti F, Raimondo G. Hepatitis B virus and hepatitis C virus dual infection. World J Gastroenterol. 2014;20(40):14559–67.
Suryasa, I. W., Rodríguez-Gámez, M., & Koldoris, T. (2021). Get vaccinated when it is your turn and follow the local guidelines. International Journal of Health Sciences, 5(3), x-xv. https://doi.org/10.53730/ijhs.v5n3.2938
Zemel R, Issachar A, Tur-Kaspa R. The role of oncogenic viruses in the pathogenesis of hepatocellular carcinoma. Clin Liver Dis. 2011;15(2):261–79.
Ng J, Wu J. Hepatitis B- and hepatitis C-related hepatocellular carcinomas in the United States: similarities and differences. Hepat Mon. 2012;12(10 HCC):7635.
Yanti, R., Sinrang, A. W., & Aminuddin, A. (2021). Levels of c-reactive protein (CRP) in stunting and non stunting tolls age 36-60 months. International Journal of Health & Medical Sciences, 4(1), 150-154. https://doi.org/10.31295/ijhms.v4n1.1667
Wong PY, Xia V, Imagawa DK, Hoefs J, Hu K-Q. Clinical presentation of hepatocellular carcinoma (HCC) in Asian-Americans versus non-Asian-Americans. J Immigr Minor Heal. 2011;13(5):842–8.
Published
How to Cite
Issue
Section
Copyright (c) 2022 International journal of health sciences
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
Articles published in the International Journal of Health Sciences (IJHS) are available under Creative Commons Attribution Non-Commercial No Derivatives Licence (CC BY-NC-ND 4.0). Authors retain copyright in their work and grant IJHS right of first publication under CC BY-NC-ND 4.0. Users have the right to read, download, copy, distribute, print, search, or link to the full texts of articles in this journal, and to use them for any other lawful purpose.
Articles published in IJHS can be copied, communicated and shared in their published form for non-commercial purposes provided full attribution is given to the author and the journal. Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgment of its initial publication in this journal.
This copyright notice applies to articles published in IJHS volumes 4 onwards. Please read about the copyright notices for previous volumes under Journal History.
